ARA-290 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

ARA-290

Also known as: cibinetide, pHBSP, pyroglutamate helix B surface peptide, ARA290, ARA 290, helix B surface peptide, HBSP

Non-hematopoietic erythropoietin-derived peptide / Innate Repair Receptor (IRR) agonist

Research chemicalLast updated: November 4, 2026Based on 36 peer-reviewed studies

What it is

Researchers and clinicians in some countries are studying ARA-290 for neuropathic pain and small fiber neuropathy, particularly in people with sarcoidosis or diabetes. It activates a protective pathway that helps repair and reduce inflammation in nerves and organs. Not FDA-approved; WADA-prohibited; completed Phase 2 studies with promising results.

The scientific side

ARA-290 is an 11-amino acid linear non-hematopoietic peptide modeled from the three-dimensional structure of the helix B region of erythropoietin (EPO). It selectively binds and activates the innate repair receptor (IRR), a heterodimeric complex composed of the EPO receptor (EPOR) and the β-common receptor (CD131/βcR), which is pharmacologically distinct from the EPOR homodimer that mediates erythropoiesis. The IRR is typically not expressed by normal tissues but is rapidly induced by injury or inflammation. ARA-290 activation of the IRR triggers anti-inflammatory, anti-apoptotic, antioxidant, and tissue-protective signaling cascades — including inhibition of NF-κB, modulation of JAK2/PI3K-AKT pathways, and suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) — without stimulating erythropoiesis or the hematopoietic side effects associated with native EPO. A short plasma half-life (~2 minutes) has been reported, yet the peptide activates a molecular switch that triggers sustained biological effects. ARA-290 also directly inhibits TRPV1 channel activity, providing an additional peripheral analgesic mechanism. Through βCR-dependent signaling, it suppresses spinal microglia activation, reduces allodynia, and promotes small nerve fiber regeneration.

Class: Non-hematopoietic erythropoietin-derived peptide / Innate Repair Receptor (IRR) agonist

Legal & regulatory status

US FDA

Not approved; described in reviewed literature as unapproved by the U.S. Food and Drug Administration. Listed as a prohibited substance by WADA and subject to sports doping detection methods.

WADA

Prohibited; listed on the WADA prohibited substances list and subject to mandatory doping control screening

Health Canada

Not stated in reviewed literature — requires manual verification